Diabetology

Diabetology Ltd is a biopharmaceutical company dedicated to the research and development of bioactive substances and compounds for the treatment of diabetes. The company focuses on developing Capsulin, an oral capsule formulation of recombinant human insulin for treating type 1 and type 2 diabetes; an oral GLP-1 analog for treating type 2 diabetes; and Combulin, an oral combination therapy for major indications of type 2 diabetes. It has developed Capsulin as an oral antidiabetic medication for treating patients with type 2 diabetes and as an alternative to insulin injections for patients with type 1 and type 2 diabetes. The company was founded in 2002 and is headquartered in St. Helier, Channel Islands. It has research and business development locations in London, UK, and Karlsruhe, Germany.